Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.49 |
| ▸ | PI4KA | P42356 | 3/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30332114 | 1.00 | ADORA2A (0.49) | ADORA2AADORA3ADORA1PI4KAPI4K2B | |
| SCHEMBL786016 | 0.98 | ADORA2A (0.50) | ADORA2AADORA3ADORA1PI4KAPI4K2B | |
| SCHEMBL30584024 | 0.98 | ADORA2A (0.50) | ADORA2AADORA3ADORA1PI4KAPI4K2B | |
| SCHEMBL16714635 | 0.97 | ADORA2A (0.49) | ADORA2AADORA3ADORA1PI4KAPI4K2B | |
| SCHEMBL786767 | 0.93 | LMNA (0.50) | ADORA2AADORA3ADORA1LMNATP53 | |
| SCHEMBL30332447 | 0.93 | LMNA (0.50) | ADORA2AADORA3ADORA1LMNATP53 | |
| Diaminooctane SCHEMBL6920367 | 0.89 | FLT3 (0.46) | ADORA2AADORA3ADORA1PI4KAPI4K2B | |
| SCHEMBL30677364 | 0.86 | LMNA (0.48) | ADORA2AADORA3ADORA1LMNATP53 | |
| SCHEMBL11961123 | 0.86 | LMNA (0.48) | ADORA2AADORA3ADORA1LMNATP53 | |
| SCHEMBL30677298 | 0.85 | LMNA (0.44) | ADORA2AADORA3ADORA1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346601-A1 | HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND THERAPY OF CIRCADIAN RHYTHM DISORDERS | UNIV PALACKEHO (CZ) | 2025-11-13 | — | — | US | disclosed |
| EP-4532498-B1 | HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND THERAPY OF CIRCADIAN RHYTHM DISORDERS | UNIV PALACKEHO (CZ) | 2025-10-29 | — | — | EP | disclosed |
| EP-4532498-A1 | HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND THERAPY OF CIRCADIAN RHYTHM DISORDERS | Univerzita Palackého v Olomouci (CZ) | 2025-04-09 | — | — | EP | disclosed |
| US-20240352016-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | TAIZHOU EOC PHARMA CO., LTD (CN) | 2024-10-24 | — | — | US | disclosed |
| WO-2024125532-A1 | NOVEL HETEROCYCLIC COMPOUND ACTING AS CDKS INHIBITOR, AND USE THEREOF | 杭州德睿智药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| WO-2023016477-A9 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2024-04-25 | — | — | WO | disclosed |
| CN-117916235-A | Cyclin dependent kinase inhibitors | 泰州亿腾景昂药业股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023232171-A1 | HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND THERAPY OF CIRCADIAN RHYTHM DISORDERS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023016477-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2023-02-16 | — | — | WO | disclosed |
| CN-110903289-B | Purine-aminomethyl-pyridone derivative, preparation method and application thereof | 四川大学 | 2023-02-03 | — | — | CN | disclosed |
| US-6413974-B1 | INHIBITORS OF CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; PREVENTING APOPTOSIS IN NEURONAL CELLS; ANTINEOPLASTIC AGENTS; NEURONAL INJURY AND DEGENERATION; CEREBROVASCULAR DISEASE | AVENTIS PHARMACEUTICALS INC. | 2002-07-02 | — | — | US | disclosed |
| WO-2002042303-A2 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| EP-1183256-A1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2002-03-06 | — | — | EP | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-1056745-A2 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-2000071543-A1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2000-11-30 | — | — | WO | disclosed |
| US-6132957-A | CONTACTING A 9-SUBSTITUTED ADENINE WITH A CELL EXTRACT CONTAINING ADENYLATE CYCLASE ACTIVITY, DETECTING THE AMOUNT OF INHIBITION, AND CORRELATING WITH TEST STANDARD OR CONTROL; NOVEL THERAPIES FOR CARDIOVASCULAR DISORDERS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2000-10-17 | — | — | US | disclosed |
| WO-1999043676-A2 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| US-5795756-A | Method and compounds for the inhibition of adenylyl cyclase | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 1998-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346601-A1 | HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND THERAPY OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | ADORA2A 459/4885ADORA3 690/4885ADORA1 529/4885 |
| US-20240352016-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | CDK2, CCNK, CDK1 | ADORA2A 3920/4885ADORA3 4638/4885ADORA1 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.